Type 2 diabetes remission possible with Weight loss programme: DIRECT TRIAL

Written By :  MD Editorial Team
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-04-07 04:15 GMT   |   Update On 2022-04-07 04:40 GMT
Advertisement

Diabetes is a growing burden, 37.3 million Americans, or 11.3% of the population, had diabetes in 2019. Diagnosed and undiagnosed, of the 37.3 million adults with diabetes, 28.7 million were diagnosed, and 8.5 million were undiagnosed.

The DiRECT trial published in The Lancet- Diabetes and Endocrinology, assessed remission of type 2 diabetes during a primary care-led weight-management programme. At 1 year, 68 (46%) of 149 intervention participants were in remission and 36 (24%) had achieved at least 15 kg weight loss.

Advertisement

DiRECT an open-label, cluster-randomised, controlled trial were practices were randomly assigned (1:1) via a computer-generated list to provide an integrated structured weight-management programme. Allocation was concealed from the study statisticians; participants, carers, and study research assistants were aware of allocation. Individuals aged 20–65 years,were included in the study with less than 6 years' duration of type 2 diabetes, BMI 27–45 kg/m2, and not receiving insulin between July 25, 2014, and Aug 5, 2016. The co primary outcomes, analysed hierarchically in the intention-to-treat population at 24 months, were weight loss of at least 15 kg, and remission of diabetes, defined as HbA1c less than 6•5% (48 mmol/mol) after withdrawal of antidiabetes drugs at baseline (remission was determined independently at 12 and 24 months).

The results of the study were

• There were 149 participants per group. At 24 months, 11% intervention participants and 2% control participants had weight loss of at least 15 kg, adjusted odds ratio [aOR] 7•49, and 53 (36%) intervention participants and five (3%) control participants had remission.

• The adjusted mean difference between the control and intervention groups in change in bodyweight was −5•4 kg and in HbA1c was −4•8 mmol/mol, despite only 51 (40%) of 129 patients in the intervention group using anti-diabetes medication compared with 120 (84%) of 143 in the control group.

• In a post-hoc analysis of the whole study population, of those participants who maintained at least 10 kg weight loss (45 of 272 with data), 29 (64%) achieved remission; 36 (24%) of 149 participants in the intervention group maintained at least 10 kg weight loss.

• Serious adverse events were similar to those reported at 12 months, but were fewer in the intervention group than in the control group in the second year of the study (nine vs 22).

Researchers concluded that "The DiRECT programme sustained remissions at 24 months for more than a third of people with type 2 diabetes. Sustained remission was linked to the extent of sustained weight loss."

Reference: https://doi.org/10.1016/S2213-8587(19)30068-3

Tags:    
Article Source : The Lancet- Diabetes and Endocrinology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News